What is the share price of Onesource Specialty Pharma Ltd (ONESOURCE) today?
The share price of ONESOURCE as on 4th February 2026 is ₹1166. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Onesource Specialty Pharma Ltd (ONESOURCE) share?
The past returns of Onesource Specialty Pharma Ltd (ONESOURCE) share are- Past 1 week: -14.14%
- Past 1 month: -34.42%
- Past 3 months: -37.29%
- Past 6 months: -38.60%
- Past 1 year: -21.44%
- Past 3 years: N/A%
- Past 5 years: -31.13%
What are the peers or stocks similar to Onesource Specialty Pharma Ltd (ONESOURCE)?
The peers or stocks similar to Onesource Specialty Pharma Ltd (ONESOURCE) include:What is the market cap of Onesource Specialty Pharma Ltd (ONESOURCE) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Onesource Specialty Pharma Ltd (ONESOURCE) is ₹13497.79 Cr as of 4th February 2026.What is the 52 week high and low of Onesource Specialty Pharma Ltd (ONESOURCE) share?
The 52-week high of Onesource Specialty Pharma Ltd (ONESOURCE) is ₹2248 and the 52-week low is ₹1057.What is the PE and PB ratio of Onesource Specialty Pharma Ltd (ONESOURCE) stock?
The P/E (price-to-earnings) ratio of Onesource Specialty Pharma Ltd (ONESOURCE) is -751.55. The P/B (price-to-book) ratio is 2.30.Which sector does Onesource Specialty Pharma Ltd (ONESOURCE) belong to?
Onesource Specialty Pharma Ltd (ONESOURCE) belongs to the Health Care sector & Biotechnology sub-sector.How to buy Onesource Specialty Pharma Ltd (ONESOURCE) shares?
You can directly buy Onesource Specialty Pharma Ltd (ONESOURCE) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Onesource Specialty Pharma Ltd
ONESOURCE Share Price
1,166.000.99% (-11.60)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
ONESOURCE Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
AvgAverage profitability - not good, not bad
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
ONESOURCE Performance & Key Metrics
ONESOURCE Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 671.87 | 2.30 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 35.50 | 5.64 | 0.61% |
100%
Analysts have suggested that investors can buy this stock
from 3 analysts
Price Upside
Earnings Growth
Rev. Growth
ONESOURCE Company Profile
OneSource Specialty Pharma Ltd is a contract development and manufacturing organization specializing in complex biologics, biosimilars, and vaccines.
BIOCON
PE Ratio
59.50
59.50
1Y Return
2.15%
2.15%
Buy Reco %
76.47
76.47
ANTHEM
PE Ratio
75.59
75.59
1Y Return
16.83%
16.83%
Buy Reco %
75.00
75.00
SAILIFE
PE Ratio
109.15
109.15
1Y Return
28.46%
28.46%
Buy Reco %
100.00
100.00
ACUTAAS
PE Ratio
101.60
101.60
1Y Return
59.41%
59.41%
Buy Reco %
100.00
100.00
PANACEABIO
PE Ratio
-270.77
-270.77
1Y Return
4.43%
4.43%
Buy Reco %
0.00
0.00
ONESOURCE Sentiment Analysis
ONESOURCE Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
ONESOURCE Stock Summary · January 2026
The company is currently grappling with regulatory delays, particularly in Canada, which have hindered revenue recognition and impacted EBITDA, yet it remains optimistic about future growth, projecting significant revenue increases starting in FY '27. With a focus on enhancing operational readiness and securing long-term contracts, management is confident in achieving its revenue and EBITDA targets for FY '28, despite near-term challenges. The strategic investment of over $100 million in capital expenditures aims to bolster production capabilities and meet rising customer demand, particularly in emerging markets. Additionally, recent regulatory changes are expected to enhance the competitive landscape for biosimilars, positioning the company favorably as it navigates supply chain constraints and seeks to capitalize on market opportunities.
ONESOURCE Stock Growth Drivers
ONESOURCE Stock Growth Drivers
7Regulatory Approvals and Market Readiness
The company is actively working towards securing regulatory approvals, particularly for semaglutide, which is critical
Capacity Expansion and Investment
The company is investing over INR 700 crores in capital expenditures to enhance its production
ONESOURCE Stock Challenges
ONESOURCE Stock Challenges
4Revenue Decline Due to Regulatory Delays
The company experienced a significant revenue decline of nearly US$10 million in Q3 FY '26
Operational Challenges and Capacity Utilization
The company faces operational challenges, particularly in capacity utilization. While the headline capacity for the
ONESOURCE Forecast
ONESOURCE Forecasts
Price
Revenue
Earnings
ONESOURCE Share Price Forecast
ONESOURCE Share Price Forecast
2026
Current
₹1,177.60
Baseline
Forecast for Feb 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹1,177.60
Baseline
Forecast for Feb 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
ONESOURCE Company Revenue Forecast
ONESOURCE Company Revenue Forecast
2025
Current
₹1.46
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2025
Current
₹1.46
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
ONESOURCE Stock EPS (Earnings Per Share) Forecast
ONESOURCE Stock EPS (Earnings Per Share) Forecast
2025
Current
₹-2.33
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹-2.33
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
ONESOURCE
ONESOURCE
Income
Balance Sheet
Cash Flow
Annual Normal View
ONESOURCE Income Statement
ONESOURCE Income Statement
Annual Normal View
| Financial Year | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2.30 | 22.40 | 131.85 | 41.40 | 176.15 | 1,462.32 | 1,435.15 | |||||||
Raw Materials | 0.00 | 20.52 | 4.89 | 82.44 | 181.82 | 404.93 | 1,035.17 | |||||||
| Power & Fuel Cost | 5.15 | 8.65 | 17.77 | 20.55 | 20.42 | 38.32 | ||||||||
| Employee Cost | 26.67 | 35.60 | 53.36 | 72.80 | 79.36 | 215.26 | ||||||||
| Selling & Administrative Expenses | 13.96 | 11.44 | 27.01 | 44.23 | 60.63 | 196.26 | ||||||||
| Operating & Other expenses | 39.71 | 16.53 | 160.51 | 507.99 | 59.34 | 235.10 | ||||||||
EBITDA | -83.19 | -70.34 | -131.69 | -686.61 | -225.42 | 372.45 | 399.98 | |||||||
| Depreciation/Amortization | 28.81 | 34.40 | 53.07 | 65.68 | 76.29 | 273.88 | 275.76 | |||||||
| PBIT | -112.00 | -104.74 | -184.76 | -752.29 | -301.71 | 98.57 | 124.22 | |||||||
| Interest & Other Items | 27.79 | 15.82 | 46.50 | 47.55 | 89.45 | 166.32 | 133.08 | |||||||
| PBT | -139.79 | -120.56 | -231.26 | -799.84 | -391.16 | -67.75 | -8.86 | |||||||
| Taxes & Other Items | 0.00 | 0.27 | -0.11 | 0.00 | 0.00 | -49.79 | -28.95 | |||||||
| Net Income | -139.79 | -120.83 | -231.15 | -799.84 | -391.16 | -17.96 | 20.09 | |||||||
| EPS | -147.92 | -97.12 | -101.98 | -37.19 | -17.77 | -2.33 | 1.76 | |||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
ONESOURCE Company Updates
FY 2026FY 2026
Investor Presentation
Jan 23PDF
Nov 12PDF
ONESOURCE Stock Peers
ONESOURCE Past Performance & Peer Comparison
ONESOURCE Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareBiotechnology
Compare valuation on Screener
Health CareBiotechnology
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Onesource Specialty Pharma Ltd | -751.55 | 2.30 | — |
| Biocon Ltd | 59.50 | 2.18 | 0.10% |
| Anthem Biosciences Ltd | 75.59 | 14.16 | — |
| Sai Life Sciences Ltd | 109.15 | 8.73 | — |
ONESOURCE Stock Price Comparison
Compare ONESOURCE with any stock or ETFCompare ONESOURCE with any stock or ETF
ONESOURCE
ONESOURCE Holdings
ONESOURCE Shareholdings
ONESOURCE Promoter Holdings Trend
ONESOURCE Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
ONESOURCE Institutional Holdings Trend
ONESOURCE Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
ONESOURCE Shareholding Pattern
ONESOURCE Shareholding Pattern
ONESOURCE Shareholding History
ONESOURCE Shareholding History
Foreign Institutions
Mutual Funds Invested in ONESOURCE
Mutual Funds Invested in ONESOURCE
No mutual funds holding trends are available
Top 5 Mutual Funds holding Onesource Specialty Pharma Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 3.8113% | Percentage of the fund’s portfolio invested in the stock 3.41% | Change in the portfolio weight of the stock over the last 3 months 0.53% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 12/39 (+5) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.4342% | Percentage of the fund’s portfolio invested in the stock 0.73% | Change in the portfolio weight of the stock over the last 3 months -0.03% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 86/155 (-1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.1410% | Percentage of the fund’s portfolio invested in the stock 3.54% | Change in the portfolio weight of the stock over the last 3 months 0.19% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 12/38 (-2) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing ONESOURCE stock
smallcases containing ONESOURCE stock
Looks like this stock is not in any smallcase yet.
ONESOURCE Events
ONESOURCE Events
ONESOURCE Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ONESOURCE has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
ONESOURCE Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ONESOURCE has not given any dividends in last 5 years
ONESOURCE Dividends
ONESOURCE Dividends
Hmm, looks like data is unavailable here. Please come back after some timeONESOURCE Stock News & Opinions
ONESOURCE Stock News & Opinions
Articles & Videos
Spotlight
OneSource Specialty Pharma Ltd leads losers in 'A' group
SBFC Finance Ltd, Syngene International Ltd, JSW Energy Ltd and Avantel Ltd are among the other losers in the BSE's 'A' group today, 27 January 2026.OneSource Specialty Pharma Ltd tumbled 18.35% to Rs 1169.8 at 14:46 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 1.17 lakh shares were traded on the counter so far as against the average daily volumes of 6142 shares in the past one month.SBFC Finance Ltd lost 11.37% to Rs 90.05. The stock was the second biggest loser in 'A' group.On the BSE, 26.8 lakh shares were traded on the counter so far as against the average daily volumes of 2.51 lakh shares in the past one month.Syngene International Ltd crashed 10.03% to Rs 488.15. The stock was the third biggest loser in 'A' group.On the BSE, 6.61 lakh shares were traded on the counter so far as against the average daily volumes of 36060 shares in the past one month.JSW Energy Ltd dropped 8.49% to Rs 437.9. The stock was the fourth biggest loser in 'A' group.On the BSE, 9.32 lakh shares were traded on the counter so far as against the average daily volumes of 91637 shares in the past one month.Avantel Ltd pared 7.26% to Rs 126.45. The stock was the fifth biggest loser in 'A' group.On the BSE, 4.58 lakh shares were traded on the counter so far as against the average daily volumes of 1.07 lakh shares in the past one month.Powered by Capital Market - Live
1 week agoCapital Market - Live
Earnings
OneSource Specialty Pharma reports consolidated net loss of Rs 88.70 crore in the December 2025 quarter
Net Loss of OneSource Specialty Pharma reported to Rs 88.70 crore in the quarter ended December 2025 as against net loss of Rs 68.85 crore during the previous quarter ended December 2024. Sales declined 26.04% to Rs 290.34 crore in the quarter ended December 2025 as against Rs 392.56 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales290.34392.56 -26 OPM %5.9736.14 - PBDT-16.28102.78 PL PBT-85.9234.02 PL NP-88.70-68.85 -29 Powered by Capital Market - Live
1 week agoCapital Market - Live
Corporate
OneSource Specialty Pharma to declare Quarterly Results
OneSource Specialty Pharma will hold a meeting of the Board of Directors of the Company on 23 January 2026.Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Corporate
OneSource Specialty Pharma allots 23,000 equity shares under ESOP
OneSource Specialty Pharma has allotted 23,000 equity shares under ESOP on 09 December 2025. Consequent to the above allotment, the paid-up share capital of the Company has increased from Rs 11,45,62,136/- (constituting of 11,45,62,136 equity shares of Re 1/- each) to Rs 11,45,85,136/- (constituting of 11,45,85,136 equity shares of Re 1/- each). Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
OneSource Specialty Pharma reports consolidated net profit of Rs 10.49 crore in the September 2025 quarter
Net profit of OneSource Specialty Pharma reported to Rs 10.49 crore in the quarter ended September 2025 as against net loss of Rs 42.08 crore during the previous quarter ended September 2024. Sales rose 12.49% to Rs 375.76 crore in the quarter ended September 2025 as against Rs 334.05 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales375.76334.05 12 OPM %28.3423.14 - PBDT75.5736.65 106 PBT5.74-31.63 LP NP10.49-42.08 LP Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
OneSource Specialty Pharma schedules board meeting
OneSource Specialty Pharma will hold a meeting of the Board of Directors of the Company on 11 November 2025.Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
OneSource Specialty Pharma to hold AGM
OneSource Specialty Pharma announced that the 18th Annual General Meeting(AGM) of the company will be held on 22 September 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Outcome of board meeting of OneSource Specialty Pharma
The Board of OneSource Specialty Pharma at its meeting held on 04 August 2025 has given their in-principle approval to evaluate potential acquisition of the Sterile Injectable CDMO and CMO businesses of Steriscience and Carbapenem facility of Brooks Steriscience. The potential transaction, if finalised and consummated, will bring in the following facilities into OneSource: - USFDA-approved sterile fill-finish manufacturing facility in Warsaw, Poland, with the ability to expand capacity for drug-device combination products for our global partners. This site serves marquee global players and several IP-led products. 'h - An integrated, state-of-the-art, USFDA-approved carbapenem facility in Vadodara, India operated under the name of Brooks Steriscience. Steriscience SG and Brooks Steriscience Limited are majorly owned directly/ indirectly by the Promoters of the Company.Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
OneSource Specialty Pharma reports consolidated net loss of Rs 0.19 crore in the June 2025 quarter
Net Loss of OneSource Specialty Pharma reported to Rs 0.19 crore in the quarter ended June 2025 as against net loss of Rs 5.55 crore during the previous quarter ended June 2024. Sales rose 11.97% to Rs 327.27 crore in the quarter ended June 2025 as against Rs 292.29 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales327.27292.29 12 OPM %27.0422.00 - PBDT66.2726.23 153 PBT-1.53-42.12 96 NP-0.19-5.55 97 Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
OneSource Specialty Pharma to hold board meeting
OneSource Specialty Pharma will hold a meeting of the Board of Directors of the Company on 4 August 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 263.63%, vs industry avg of 21.23%
Over the last 5 years, market share increased from 0.03% to 6.12%